PRD003
Lysosomal Acid Lipase Deficiency (LAL-D)
DiscoveryActive
Key Facts
About PRD Therapeutics
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
View full company profile